A prospective trial at MD Anderson Cancer Center assessed the impact of CD34+ cell dose on the outcomes of patients with MM (73%) or light chain amyloidosis who underwent auto-HCT and received either a standard (4–6 × 106 CD34+ cells/kg) or high-dose (10–15 × 106 CD34+ cells/kg). The gene discussed is CD34; the disease is Miyoshi myopathy.